By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Ipratropium (systemic, oral inhalation) (monograph)
Drugs

Ipratropium (systemic, oral inhalation) (monograph)

https://themeditary.com/drug/ipratropium-systemic-oral-inhalation-monograph-6865.html
Medically Reviewed by Oluni Odunlami, MD TheMediTary.Com | Reviewed: Aug 14, 2023  Additional Content by TheMediTary.Com

Generic name: atrovent

Availability: Prescription only

Pregnancy & Lactation: Risk data available

Brand names: Atrovent hfa, Ipratropium inhalation

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

What is Ipratropium (systemic, oral inhalation) (monograph)?

Introduction

Bronchodilator; a nonselective, competitive antagonist at muscarinic receptors.

Uses for Ipratropium (Systemic, Oral Inhalation)

Bronchospasm in COPD

Long-term treatment of reversible bronchospasm associated with COPD, including chronic bronchitis and emphysema.

Fixed combination with albuterol sulfate is used for the symptomatic management of bronchospasm associated with COPD in patients who continue to have evidence of bronchospasm despite the regular use of an orally inhaled bronchodilator and who require a second bronchodilator.

Bronchospasm in Asthma

Has been used for symptomatic treatment of acute or chronic bronchial asthma† [off-label]; β2-adrenergic agonist bronchodilators generally preferred initially for relief of bronchospasm in asthmatic patients.

May be useful as alternative therapy in adults experiencing adverse effects (e.g., tachycardia, arrhythmia, tremor) with a β-adrenergic agonist† [off-label].

Some clinicians consider ipratropium as adjunctive therapy in patients with moderate or severe exacerbations (peak expiratory flow rate ≤80% of predicted) of asthma† [off-label] who fail to respond adequately to β-adrenergic agonists and corticosteroids.

May be useful for prevention or reversal of bronchospasm induced by β-adrenergic blocking agents† [off-label] (e.g., propranolol) in asthmatic patients; β-adrenergic bronchodilators generally ineffective for this indication in such patients.

Ipratropium (Systemic, Oral Inhalation) Dosage and Administration

Administration

Administer by oral inhalation using an oral aerosol inhaler or via nebulization.

Oral Inhalation via Metered-dose Aerosol

Ipratropium Bromide

Aerosol delivers ≥200 metered sprays per canister.

Patient should be instructed to clear excessive sputum from chest before inhalation.

Shake well immediately prior to use. Actuate aerosol inhaler 3 times prior to the initial use or if it has not been used for >24 hours.

Do not use mouthpiece for other aerosol drugs.

Exhale slowly and completely and place the mouthpiece of the inhaler well into the mouth with the lips closed around it. To avoid contact of the drug with the eyes and subsequent adverse effects, close eyes during inhalation of aerosol. Inhale slowly and deeply through the mouth while actuating the inhaler. Hold the breath for 10 seconds, withdraw the mouthpiece, and exhale slowly.

Allow ≥15 seconds to elapse between subsequent inhalations from the aerosol inhaler.

Wash the mouthpiece in hot running water as needed. If soap is used, rinse mouthpiece thoroughly with plain water.

Ipratropium Bromide and Albuterol Sulfate

Aerosol delivers ≥200 metered sprays per canister.

Shake well immediately prior to use. Actuate 3 times prior to the initial use or if it has not been used for >24 hours. Do not use actuator provided for other aerosol drugs. To avoid contact of the drug with the eyes and subsequent adverse effects, close eyes during inhalation of aerosol.

Exhale deeply and place mouthpiece of the inhaler into the mouth. Inhale slowly and deeply through the mouth while actuating the inhaler. Hold the breath for 10 seconds, withdraw the mouthpiece, and exhale slowly. Allow approximately 2 minutes to elapse and repeat the procedure. Rinse the mouthpiece in hot water as needed. If soap is used, rinse the mouthpiece thoroughly with plain water. When dry, replace the cap on the mouthpiece when the inhaler is not in use.

Oral Inhalation via Nebulization

Ipratropium Bromide

Empty entire contents of the single-use vial of solution into the nebulizer reservoir and attach reservoir to the mouthpiece or face mask and to the compressor according to the manufacturer’s instructions.

Use care when a face mask is used to avoid leakage since transient blurred vision and other adverse effects may result if the drug enters the eyes. (See Ocular Effects under Cautions.) Use of a mouthpiece may avoid inadvertent entry of drug into the eye.

Place the mouthpiece of the nebulizer in the mouth or put on the nebulizer face mask. Breathe as calmly, deeply, and evenly as possible until the nebulizer stops producing mist.

Duration of treatment usually is about 5–15 minutes.

Ipratropium Bromide and Albuterol Sulfate

Empty entire contents of the single-use vial of solution into the nebulizer reservoir and attach reservoir to the mouthpiece or face mask and to the compressor according to the manufacturer’s instructions.

Place the mouthpiece of the nebulizer in the mouth or put on the nebulizer face mask. Breathe as calmly, deeply, and evenly as possible until the nebulizer stops producing mist.

Duration of treatment usually is about 5–15 minutes.

Clean the nebulizer after use according to the manufacturer’s instructions.

Dosage

Available as ipratropium bromide.

Dosage of oral inhalation aerosol expressed in terms of the monohydrate.

Dosage of inhalation solution for nebulization expressed in terms of anhydrous drug.

Using in vitro testing at an average flow rate of 3.6 L per minute for an average of ≤15 minutes, the Pari-LC Plus nebulizer delivered at the mouthpiece approximately 46 or 42% of the original dosage of albuterol or ipratropium bromide, respectively.

Pediatric Patients

COPD
Inhalation

Patients ≥12 years of age: 36 mcg (2 inhalations) 4 times daily via a metered-dose aerosol, given alone or in fixed combination with albuterol (90 mcg via the mouthpiece). Additional inhalations should not exceed 216 mcg (12 inhalations) of ipratropium bromide in 24 hours.

Patients ≥12 years of age: 500 mcg (contents of 1 unit-dose vial) 3 or 4 times daily (i.e., every 6–8 hours) via a nebulizer.

Adults

COPD
Inhalation

Initially, 36 mcg (2 inhalations) 4 times daily via a metered-dose aerosol, given alone or in fixed combination with albuterol (90 mcg from the mouthpiece). Additional inhalations should not exceed 216 mcg (12 inhalations) in 24 hours.

Initially, 500 mcg 3 or 4 times daily (i.e., every 6–8 hours) via a nebulizer. With ipratropium bromide in fixed combination with albuterol sulfate (DuoNeb), 500 mcg 4 times daily. Additional inhalations should not exceed 6 inhalations daily.

Prescribing Limits

Pediatric Patients

COPD
Inhalation

Maximum 216 mcg (12 inhalations via a metered-dose inhaler) in 24 hours.

Maximum 12 inhalations via metered-dose inhaler in 24 hours with the fixed combination of ipratropium bromide and albuterol sulfate.

500 mcg 3–4 times daily via a nebulizer in patients ≥12 years of age.

Adults

COPD
Inhalation

Maximum 216 mcg (12 inhalations via a metered-dose inhaler) in 24 hours; frequency of administration should not exceed 4 times daily.

Maximum 12 inhalations via metered-dose inhaler in 24 hours with the fixed combination of ipratropium bromide and albuterol sulfate.

500 mcg 3–4 times daily via a nebulizer.

Special Populations

Geriatric Patients

Dosage adjustments based solely on age are not necessary.

Detailed Ipratropium dosage information

Warnings

Contraindications

  • Known hypersensitivity to the drug or any other component of the formulation, or to atropine or its derivatives.

  • Known hypersensitivity to soya lecithin or related food products, including soybeans and peanuts.

Warnings/Precautions

Warnings

Acute Bronchospasm

Delayed onset of action; not indicated for initial treatment. Generally should not be used alone for the management of acute bronchospasm, when a rapid response is required.

Sensitivity Reactions

Immediate hypersensitivity reactions, including rash, angioedema of the tongue, lips, and face, urticaria, bronchospasm, oropharyngeal edema, and anaphylactic reaction.

Possible paradoxical bronchospasm.

General Precautions

Worsening COPD

Contact a clinician immediately if a previously effective dosage regimen fails to provide the usual relief (e.g., need to increase the dose or frequency of administration of the drug). Do not increase the dose or frequency of inhalation without consultation with a clinician.

Ocular Effects

Possible temporary blurred vision, mydriasis, ocular pain, conjunctival or corneal congestion associated with visual halos or colored images, or precipitation or worsening of angle-closure glaucoma following inadvertent contact of ipratropium with the eyes.

Minimize ocular exposure by using a mouthpiece rather than a face mask during administration via a nebulizer. During oral inhalation of aerosol, close eyes. Inhalation aerosol should not be administered using the open-mouth technique in these patients with angle-closure glaucoma. Use with caution in patients with angle-closure glaucoma.

Genitourinary Effects

Possible urinary retention/difficulty, urinary tract infection, or dysuria.

Use with caution in patients with bladder neck obstruction or prostatic hypertrophy.

Cardiovascular Effects

Possible adverse cardiovascular effects (e.g., tachycardia, palpitations, aggravated hypotension or hypertension).

Use of Fixed Combination

When used in fixed combination with other agents, consider the cautions, precautions, and contraindications associated with the concomitant agents.

Specific Populations

Pregnancy

Category B.

Lactation

Use with caution.

Pediatric Use

Safety and efficacy of oral inhalation not established in children <12 years of age.

Hepatic Impairment

Use with caution.

Renal Impairment

Use with caution.

Common Adverse Effects

Bronchitis, upper respiratory tract infection, cough, and dryness of the mouth, throat, or tongue with ipratropium aerosol. Adverse effects resulting in discontinuance of nebulized ipratropium most frequently include bronchitis, dyspnea, and bronchospasm.

How should I use Ipratropium (systemic, oral inhalation) (monograph)

Administration

Administer by oral inhalation using an oral aerosol inhaler or via nebulization.

Oral Inhalation via Metered-dose Aerosol

Ipratropium Bromide

Aerosol delivers ≥200 metered sprays per canister.

Patient should be instructed to clear excessive sputum from chest before inhalation.

Shake well immediately prior to use. Actuate aerosol inhaler 3 times prior to the initial use or if it has not been used for >24 hours.

Do not use mouthpiece for other aerosol drugs.

Exhale slowly and completely and place the mouthpiece of the inhaler well into the mouth with the lips closed around it. To avoid contact of the drug with the eyes and subsequent adverse effects, close eyes during inhalation of aerosol. Inhale slowly and deeply through the mouth while actuating the inhaler. Hold the breath for 10 seconds, withdraw the mouthpiece, and exhale slowly.

Allow ≥15 seconds to elapse between subsequent inhalations from the aerosol inhaler.

Wash the mouthpiece in hot running water as needed. If soap is used, rinse mouthpiece thoroughly with plain water.

Ipratropium Bromide and Albuterol Sulfate

Aerosol delivers ≥200 metered sprays per canister.

Shake well immediately prior to use. Actuate 3 times prior to the initial use or if it has not been used for >24 hours. Do not use actuator provided for other aerosol drugs. To avoid contact of the drug with the eyes and subsequent adverse effects, close eyes during inhalation of aerosol.

Exhale deeply and place mouthpiece of the inhaler into the mouth. Inhale slowly and deeply through the mouth while actuating the inhaler. Hold the breath for 10 seconds, withdraw the mouthpiece, and exhale slowly. Allow approximately 2 minutes to elapse and repeat the procedure. Rinse the mouthpiece in hot water as needed. If soap is used, rinse the mouthpiece thoroughly with plain water. When dry, replace the cap on the mouthpiece when the inhaler is not in use.

Oral Inhalation via Nebulization

Ipratropium Bromide

Empty entire contents of the single-use vial of solution into the nebulizer reservoir and attach reservoir to the mouthpiece or face mask and to the compressor according to the manufacturer’s instructions.

Use care when a face mask is used to avoid leakage since transient blurred vision and other adverse effects may result if the drug enters the eyes. (See Ocular Effects under Cautions.) Use of a mouthpiece may avoid inadvertent entry of drug into the eye.

Place the mouthpiece of the nebulizer in the mouth or put on the nebulizer face mask. Breathe as calmly, deeply, and evenly as possible until the nebulizer stops producing mist.

Duration of treatment usually is about 5–15 minutes.

Ipratropium Bromide and Albuterol Sulfate

Empty entire contents of the single-use vial of solution into the nebulizer reservoir and attach reservoir to the mouthpiece or face mask and to the compressor according to the manufacturer’s instructions.

Place the mouthpiece of the nebulizer in the mouth or put on the nebulizer face mask. Breathe as calmly, deeply, and evenly as possible until the nebulizer stops producing mist.

Duration of treatment usually is about 5–15 minutes.

Clean the nebulizer after use according to the manufacturer’s instructions.

Dosage

Available as ipratropium bromide.

Dosage of oral inhalation aerosol expressed in terms of the monohydrate.

Dosage of inhalation solution for nebulization expressed in terms of anhydrous drug.

Using in vitro testing at an average flow rate of 3.6 L per minute for an average of ≤15 minutes, the Pari-LC Plus nebulizer delivered at the mouthpiece approximately 46 or 42% of the original dosage of albuterol or ipratropium bromide, respectively.

Pediatric Patients

COPD
Inhalation

Patients ≥12 years of age: 36 mcg (2 inhalations) 4 times daily via a metered-dose aerosol, given alone or in fixed combination with albuterol (90 mcg via the mouthpiece). Additional inhalations should not exceed 216 mcg (12 inhalations) of ipratropium bromide in 24 hours.

Patients ≥12 years of age: 500 mcg (contents of 1 unit-dose vial) 3 or 4 times daily (i.e., every 6–8 hours) via a nebulizer.

Adults

COPD
Inhalation

Initially, 36 mcg (2 inhalations) 4 times daily via a metered-dose aerosol, given alone or in fixed combination with albuterol (90 mcg from the mouthpiece). Additional inhalations should not exceed 216 mcg (12 inhalations) in 24 hours.

Initially, 500 mcg 3 or 4 times daily (i.e., every 6–8 hours) via a nebulizer. With ipratropium bromide in fixed combination with albuterol sulfate (DuoNeb), 500 mcg 4 times daily. Additional inhalations should not exceed 6 inhalations daily.

Prescribing Limits

Pediatric Patients

COPD
Inhalation

Maximum 216 mcg (12 inhalations via a metered-dose inhaler) in 24 hours.

Maximum 12 inhalations via metered-dose inhaler in 24 hours with the fixed combination of ipratropium bromide and albuterol sulfate.

500 mcg 3–4 times daily via a nebulizer in patients ≥12 years of age.

Adults

COPD
Inhalation

Maximum 216 mcg (12 inhalations via a metered-dose inhaler) in 24 hours; frequency of administration should not exceed 4 times daily.

Maximum 12 inhalations via metered-dose inhaler in 24 hours with the fixed combination of ipratropium bromide and albuterol sulfate.

500 mcg 3–4 times daily via a nebulizer.

Special Populations

Geriatric Patients

Dosage adjustments based solely on age are not necessary.

Detailed Ipratropium dosage information
Ipratropium (systemic, oral inhalation) (monograph) Dosage information (more detail)

What other drugs will affect Ipratropium (systemic, oral inhalation) (monograph)?

Limited systemic absorption following oral inhalation; interactions with systemically administered drugs unlikely.

Specific Drugs

Drug

Interaction

Comments

Antimuscarinic agents

Potential pharmacodynamic interaction (additive effects)

Caution advised with concomitant administration

Methylxanthine derivatives

No adverse drug interactions reported

β-Adrenergic agonists

Potential pharmacodynamic interaction (additive effects)

If concomitant therapy is required, consider cautious use of cardioselective β-adrenergic blocking agents

Corticosteroids

No adverse drug interactions reported

Cromolyn sodium

No adverse drug interactions reported

More about Ipratropium (systemic, oral inhalation) (monograph) (Atrovent)

Dosage information
Ipratropium (systemic, oral inhalation) (monograph) Side Effects
During pregnancy
Ipratropium Prescribing Information
Drug images
Side effects
Breastfeeding Warnings
Drug class: Drugs

Related treatment guides

COPD, Maintenance
Asthma
Bronchiectasis
Share this Article
Contents
Uses Warnings Before Taking Dosage Side effects Interactions
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by